Palantir's AIPCon 10, Ramp Hits $44B, 60 Minutes Considers Rogan | Diet TBPN

Diet TBPN delivers the best of today’s TBPN episode in 30 minutes. TBPN is a live tech talk show hosted by John Coogan and Jordi Hays, streaming weekdays 11–2 PT on X and YouTube, with each episode posted to podcast platforms right after. Described by The New York Times as “Silicon Valley’s newest obsession,” the show has recently featured Mark Zuckerberg, Sam Altman, Mark Cuban, and Satya Nadella. TBPN is made possible by: Ramp - https://ramp.com Public - https://public.com Cisco - https://www.cisco.com Console - https://www.console.com CrowdStrike - https://www.crowdstrike.com Figma - https://www.figma.com MongoDB - https://www.mongodb.com NYSE - https://www.nyse.com Railway - https://railway.com Shopify - https://www.shopify.com/ Follow TBPN: https://TBPN.com https://x.com/tbpn https://open.spotify.com/show/2L6WMqY3GUPCGBD0dX6p00?si=674252d53acf4231 https://podcasts.apple.com/us/podcast/technology-brothers/id1772360235 https://www.youtube.com/@TBPNLive

Speaker names marked ? are inferred from speaking time and the show’s known hosts — they are not voice-verified.

• 0:02John Coogan?

  We are live from Palantir AIP Con. Big news from Ramp today. Massive fundraiser, we're going to cover it in a little bit, but first

• 0:09Jordi Hays?

  You hear that?

• 0:09John Coogan?

  We got to talk. Oh, is it still going? I like it. The Ramp song's back. This was, this was early days. We really talked about Ramp so much, turned it into a song. The topic of conversation in DC has, it's still in AI world, but instead of talking about approving models before they're released today, it's about the bio threat. Brandon Gurrell wrote in the TBP newsletter today. The great houses of AI have united behind the bio threat. There's actually a lot more to that because it was a big, long list of signatories from AI, but also from the bio world and biotech and even startups. We've seen former guests of the show sign on. I'm excited to bring some of those folks back on the show in the coming weeks and hear more

• 0:51John Coogan?

  about this because I have this belief that as AI advanced, we got cyber because it was such a tight feedback loop, such a tight verifiable reward. Reinforcement learning works really well in that context. Bio has some similar characteristics.

• 1:05Jordi Hays?

  And it was a very tangible Y2K style moment.

• 1:08John Coogan?

  Exactly.

• 1:09Jordi Hays?

  Where there was, let's just say, a powerful business strategy.

• 1:12John Coogan?

  Yeah, is it? Yeah, it was like, is it over? You start thinking about the consequences of this and you don't need to get to AGI, super intelligence god. You can just have a really powerful tool that creates a new problem and that creates full employment for Nikesh Ror over at Palo Alto Networks, who we had a chance to talk to yesterday. And he's been very fortunate in implementing the solutions to the cybersecurity threats posed by new AI systems, some of the new AI capabilities that are rolling out. But bio might be next. And so it's exciting to see that the great houses of AI are uniting behind the bio threat. So let's take you through this. So in 1981, a group of researchers published the primary structure of the polio virus genome in the journal Nature.

• 1:54John Coogan?

  So they were basically open sourcing the sequence for making polio, which Just a few years earlier, polio, I think, was on the decline by 1981, but a very, very problematic virus. It's an RNA virus, meaning that its nucleobases or building blocks are A, C, G, U, if you're familiar with RNA, adazine, cytosine, guanine, and uracil. Put more plainly, thanks, Brandon Gurrell, he says, "When the researchers published the primary structure of the polio virus, they gave the world the literal sequence of polio virus building blocks in order from start to finish. By the mid 20th century, before mass vaccination, polio was paralyzing and killing more than half a million people per year worldwide." So you have this pretty deadly virus killing

• 2:38John Coogan?

  more than half a million people per year worldwide, and you have just open sourced it. What happens? So in 2002, researchers synthesized infectious polio virus from its publicly available sequence data. So they didn't actually need any of the polio virus RNA to start. They didn't need it on hand. They didn't need to, it's not like they took a little sample and they just cloned it up and made it bigger. They just took the data and they made the actual virus. So this is the, this is the shape of the threat. If there's a new, if there's a new virus or an existing virus or a forgotten about virus and you have the code to it, you can potentially print that RNA and then have the virus in your hands, even if you don't have a sample. Instead, these researchers in 2002, they were able to take the published sequence, chemically synthesize short DNA

• 3:20John Coogan?

  fragments, assemble them into full-length, a full-length DNA copy of the polio virus genome, and then use the DNA to make the viral RNA to fully recover the infectious virus. So in 2005, researchers used these same technologies to reconstruct the Spanish Flu, a virus in 1918 that killed 675,000 Americans and had a 2% to 3% mortality rate among those infected. Very, very dangerous stuff. So basically, these two reconstructed viruses showed that having a physical virus on hand was no longer necessary as source material to create viruses. All you needed was the blueprints. As long as you have the code, literally just like text in a text file, a bunch of A, T, G, U, you can go and make this, as long as you have the equipment on hand,

• 4:01John Coogan?

  but that is getting democratized as well. And that's what this AI letter is all about. So that's a situation that we're still in today, except now that we have AI, there are easier ways to potentially reconstruct DNA sequences that could create new viruses. So yesterday, Demis Hassabis, Sam Altman, Dario Amade, Alex Wang, and dozens of other high-profile leaders across AI, tech, policy, nucleic acid synthesis, and biotech, signed an open letter. Called in support of mandatory nucleic acid synthesis, screening and record keeping. You might've seen it on the timeline and at first glance, Brandon here assumed, and I assumed the same thing, assumed it was another press release from a frontier lab claiming it had just discovered new capabilities in one of its internal models that would ultimately lead to catastrophe.

• 4:44John Coogan?

  A lot of this like doom fear based marketing has been happening. So that was sort of the natural reaction and that's what Brandon felt.

• 4:49Jordi Hays?

  Some people's reaction would be, are we not doing record keeping here already?

• 4:53John Coogan?

  That's a great question and Brandon actually did answer that, but it's not just a PR stunt and it's not a new capability. They're not saying that the models can just create a novel virus, you know, one shot, that that is solved yet. It's not there, but they see it as something that's coming down the pipe and this letter is not this dangerous new capability. It's more asking the US government to force nucleic acid synthesis companies to screen orders for sequences of concern. So, hey, somebody just ordered this, looks a lot like a virus. Like, what are we doing here? You said that you were trying to treat cancer or you said that you were, you know, trying to make a new peptide and all of a sudden you're asking for polio virus or something that looks like polio virus. Like, let's, let's dig into this. That's where they're going with that.

• 5:38John Coogan?

  They also need to verify the legitimacy of the customer and to keep a record of what they're sending and to whom. That's a crazy one that I'm sure you're like, wait, they weren't keeping records? They were a little bit. He gets into this. So he says, the reason the letter is coming out now is that the threat of nucleic acid synthesis sequence, sequencing, getting into the wrong hands has been enhanced by AI. So anyone with an AI tool in the future could in theory, if the models don't have safeguards on them, could synthesize, could create a sequence that then they go to a nucleic acid sequence company, get printed, send it to them, mix it up, boom, they got a virus. Not good. So, most of the global nucleic acid synthesis industry has already signed up to do some of this.

• 6:20John Coogan?

  They did, they started this in 2009 with what's called the International Gene Synthesis Consortium and roughly 80% of commercial synthesis is on board, but membership.

• 6:29Jordi Hays?

  Great, so 20% still just. Hanging out. No, we're good.

• 6:34John Coogan?

  Eighty percent of nuclear weapons are safely stored. Don't ask about the other 20%. That's kind of what this letter is getting at. Because 80%, it was a good first effort, 2009, it's been 16, 17 years. We haven't had, yeah, but there's a new reason to go further. Let's get that last 20%. That's what they're asking for. Membership is not a strong guarantee that they're actually screening or keeping records of their customers because it's voluntary. The 80% number is also self-reported, for example, and a bunch of other factors contribute to the relative flimsiness of the agreement. So it's not government verified.

• 7:08Jordi Hays?

  Program by just saying that you're opting into it, but then even the reporting, once you're opted in, is voluntary.

• 7:14John Coogan?

  So I, I think the way this works is the International Gene Synthesis Consortium is probably a nonprofit NGO, you know, non-governmental organization. All the companies, they volunteer, 80% of commercial synthesis volume has opted into this. And then this organization, the International Gene Synthesis Consortium, they say, hey, we've looked at the market and we're covering about 80% has opted into this. We're, we're on board with 80% and, and the government isn't coming in and checking the records. They're not actually saying, okay, well, we, we have a different number because we're the government and you have your this number. Let's verify this number. It's self-reported by that organization, but there's no reason not to trust that organization necessarily. A bunch of other factors contribute to the relative flimsiness of this agreement.

• 7:57John Coogan?

  HHS also has guidance in place around the issue, but again, it's voluntary, meaning that the possibility of bad actors getting their hands on dangerous nucleic acid sequences, at least from American companies, still cannot be ruled out. Overall, it's good to see industry leaders signing this letter and doubly refreshing that the letter is not yet another warning of apocalyptic AI doom, which I think the public has unfortunately become to expect from announcements like this. Hopefully the relevant legislators are paying attention and can make this happen in short order. So I thought that was a good, a good breakdown, and I agree with a lot of that. Andrew Curran also has some deep dive on this with some more of the signatories. He shares screenshots of all of these and it really is everyone.

• 8:38John Coogan?

  Yeah. Y Combinator, DeepMind, Microsoft, Interconnect AI, Harvard, tons of stuff. And then over in, in the nucleic acid synthesis industry, you have Twist Bioscience. Anne's Emerald Cloud Lab and Kathleen McMahon from Valthos is on here. So, good news, but obviously, and just an early step, this is just an open letter to the government saying, hey, we think you should, we want to support this. We think that the government should start thinking about this. The other news in the bio world.

• 9:09Jordi Hays?

  Yeah, I mean, the news is just that there's incredible momentum in biotech.

• 9:14John Coogan?

  It feels like it.

• 9:15Jordi Hays?

  Early-stage biotech.

• 9:16John Coogan?

  Yeah, momentum, but not like volume, not scale yet. Because you're looking at three trillion dollar IPOs going out this year, potentially. So much news in AI, Microns at a trillion, every chip stock is, you know, in the hundreds of billions, trillions. This is much smaller, but.

• 9:34Jordi Hays?

  But it's notable because biotech had been left for dead in some ways. We had a biotech investor on probably 14 months ago at this point, who said, I don't even know. I mean, just looking at the returns so far, I don't know why you would invest in this asset class. But of course, every asset class goes through that kind of phase. And clearly, there's a lot of momentum.

• 9:58John Coogan?

  And they should be, you would expect that biotech would be similarly power law driven, maybe not as extreme, but if you pull out SpaceX, OpenAI, Anthropic from.

• 10:05Jordi Hays?

  The power law is universal, though.

• 10:07John Coogan?

  Yes, but I feel like the biotech community has a little bit more of like a culture of like base hits, doubles, triples, where they flip companies pretty frequently in the.

• 10:18Jordi Hays?

  Yeah, we had that, didn't we have a guy on that had sold?

• 10:21John Coogan?

  Like three companies. We didn't have.

• 10:22Jordi Hays?

  He had two billion dollar exits.

• 10:25John Coogan?

  Yep. And then he joined another company and sold it for three billion, like the next day. And so that.

• 10:29Jordi Hays?

  So anyways, you have Isomorphic Labs spun out of DeepMind, Coinbase, or not Coinbase, but Brian spun out, or like founded New Limit. You have Retro Biosciences.

• 10:41John Coogan?

  We're going to get Jacob on the show.

• 10:43Jordi Hays?

  As well. Altos Labs.

• 10:47John Coogan?

  Jeff the Chad from Amazon has this.

• 10:51Jordi Hays?

  And then Anthropic, obviously, acquired Coefficient Bio as well.

• 10:56John Coogan?

  But Jensen and Larry Ellison at Oracle are also doing stuff. So there's a lot of activity. It's very fun. And I hope we're going to be able to cover this a lot more in the near future.

• 11:04Jordi Hays?

  Yeah. At what point do the?

• 11:08Jordi Hays?

  At what point does like a Pfizer, Johnson and Johnson start joining the press release economy of just coming, I'm not, I'm not saying it'd be a good thing, but coming, coming out and saying, we believe we're, you know, right at the.

• 11:22John Coogan?

  Because there are partnerships all the time that happen and they're always just like tucked a little bit deeper in the Wall Street Journal because AI is dominating and even private credit takes the front seat to the bio news, but there, there's a whole bunch of deal making going on. Anyway, there's other deal making going on in fintech. We're going to talk about Ramp's raise today.

• 11:40Jordi Hays?

  What's going on in Ramp land?

• 11:41John Coogan?

  Forty-four billion dollar valuation.

• 11:43Jordi Hays?

  Whoa.

• 11:43John Coogan?

  Really, really solid traction, just, you know, every 12, 18 months, sometimes much quicker. Sometimes they do two rounds in two weeks, but really solid progress. They raised $750 million at a $44 billion valuation. Last time we grew this fast, we were 1/20th of the size.

• 12:00Jordi Hays?

  Yeah, this is the most notable thing to me.

• 12:03John Coogan?

  Yeah.

• 12:03Jordi Hays?

  Lots of chatter on the timeline around, you know, other fintech valuations. You compare them.

• 12:10John Coogan?

  SaaS apocalypse.

• 12:11Jordi Hays?

  Yeah, well, yeah.

• 12:12John Coogan?

  Would you be a victim of SaaS apocalypse?

• 12:13Jordi Hays?

  Ramp is now worth more than PayPal.

• 12:15John Coogan?

  Okay.

• 12:16Jordi Hays?

  PayPal has 32 billion of revenue.

• 12:17John Coogan?

  Yeah.

• 12:18Jordi Hays?

  But PayPal certainly has, I would say, you know, probably negative momentum.

• 12:25John Coogan?

  Yeah.

• 12:25Jordi Hays?

  Whereas Ramp has incredible momentum and this, this is the standout line. They were 1/20th the size the last time they were growing this fast. And so, yeah, just really, really, really, really impressive execution.

• 12:38John Coogan?

  Yeah.

• 12:38Jordi Hays?

  And incredible opportunities still.

• 12:42John Coogan?

  Yeah. So Eric took to the timeline, posted an essay about the third pillar comparing the previous eras of value creation, the two pillars, people and vendors dating back to 600 BCE. If you're not thinking in millennia, what are you doing here? Tokens emerged as the third pillar in 2026 AD and he calls it the quadrillion token blind spot. Boil down 500 years of finance and it's really just three questions. Who spent what? Was it worth it? What's the bill next month? People get caught up in all these crazy things. I mean, you see this like marketing, I'm sure,

• 13:23John Coogan?

  and ad buying where people will do all these crazy analyses and ROI, RAS and all this other stuff. And it's always useful to zoom out and just be like, okay, we spent a bunch of money. Did the bank balance go up in this company or not?

• 13:38Jordi Hays?

  Yeah, all personal and business finance at the end eventually comes down to are we making more money than we're spending?

• 13:45John Coogan?

  Yeah. And I think, yeah, Eric is right to dive super deep into like token optimization and thinking about the tools that they're building. But then at the same time, like not, don't get lost in the sauce and like actually zoom out and try and understand like, what is the core value that you're delivering to your customer? It is answering that question. So fantastic news over there. There's some other fundraising news. Sabby, the Beanie BCI company is getting preempted at 35 million at 500 million post. This is a leak from Arfa Rock. We'll see where it goes.

• 14:18Jordi Hays?

  This is huge for you.

• 14:19John Coogan?

  Why?

• 14:19Jordi Hays?

  Because you are a beanie guy.

• 14:21John Coogan?

  I do like beanies.

• 14:22Jordi Hays?

  You love to throw a beanie in the morning.

• 14:24John Coogan?

  Keeps it together. Yeah. I like a beanie. Very, very.

• 14:28Jordi Hays?

  I, it's interesting. I think that this format, of course, I'm sure they can adapt it to other types of hats.

• 14:37John Coogan?

  Yeah.

• 14:37Jordi Hays?

  But this format certainly maybe makes it harder to build momentum in places like California, at least Southern California, Arizona.

• 14:46John Coogan?

  Be big amongst creative directors, though.

• 14:48Jordi Hays?

  Yeah.

• 14:48John Coogan?

  Huge.

• 14:49Jordi Hays?

  Huge, huge. Silver Lake, Silver Lake, you know, every.

• 14:53John Coogan?

  It's not too hard to change a beanie into a hat, cowboy hat. Like, that's just extra leather around it. You could wrap the beanie in the cowboy hat. You can wear.

• 15:01Jordi Hays?

  Here's what's interesting, though. So Arfa Rock usually.

• 15:04John Coogan?

  It's pretty dialed.

• 15:06Jordi Hays?

  Pretty dialed.

• 15:06John Coogan?

  Pretty dialed.

• 15:07Jordi Hays?

  Pretty dialed. It's almost like he has inside information. It's almost like he somehow got.

• 15:12John Coogan?

  Yeah, but I mean, we've talked about the game theory of like, does he work at a real like tier one venture capital firm that's like, what's the benefit of leaking everything? Is he a lawyer that's seeing all the docs turn around?

• 15:23Jordi Hays?

  Oh, I mean, zero benefit for a lawyer.

• 15:25John Coogan?

  Right?

• 15:26Jordi Hays?

  Um, the.

• 15:27John Coogan?

  The rush of getting likes on the timeline is pretty universal. You're a lawyer, you're just like, I need a banger.

• 15:33Jordi Hays?

  Out of fund, for sure.

• 15:35John Coogan?

  Yeah.

• 15:35Jordi Hays?

  And I don't, I don't know anything else. But he's always taken the view that.

• 15:44Jordi Hays?

  It can be helpful to the founder to build, because a bunch of people are going to see this, that this didn't sort of land in their deal flow, land on their desk, and they're going to reach out, right? So it does create momentum, but can certainly be annoying for teams as well. This was notable, though. So 200 million of LOI from B2B customers. And so, very curious what the enterprise play is here.

• 16:10John Coogan?

  Does that mean like, like through hospital networks, or through like the healthcare system? Or is it like Mark Zuckerberg wants to go further? He wants to track the brainwaves of the employees, not just the mass movements.

• 16:23Jordi Hays?

  We're going to track your screen and your brain.

• 16:26John Coogan?

  I mean, it could go either way, because you imagine like Neuralink has had a bunch of traction and a bunch of amazing. I saw Nolan, the first patient, P0, on Rogan, talking about playing COD with the Neuralink. Amazing. And you can imagine that at a certain point, like some sort of partnership.

• 16:44Jordi Hays?

  They have multiple hat form factors.

• 16:46John Coogan?

  There we go. Our hats come in.

• 16:48Jordi Hays?

  We're good. I was getting really hung up on the beanie. I'm like, there's so many different enterprise or B2B contexts. You're in a warehouse in Dallas, Texas in the summer.

• 16:58John Coogan?

  Yeah, you don't know. Maybe there's $200 million LOIs from REI or Patagonia. You don't know. Who makes beanies? What's the Carhartt? Carhartt makes a great beanie. There you go. You don't know any of this stuff. You're completely out of line.

• 17:14Jordi Hays?

  I went through, I think I went through.

• 17:15John Coogan?

  On the beanie economy.

• 17:16Jordi Hays?

  Beanie economy. Beanie market map. Goldman, very optimistic.

• 17:20John Coogan?

  What'd they say?

• 17:21Jordi Hays?

  Goldman expects SpaceX's AI revenue to surge 100 times by 2030.

• 17:26John Coogan?

  Huge.

• 17:27Jordi Hays?

  Big, big number. I looked at this title and I was thinking like, okay, what's Grok's actual revenue today if you take out?

• 17:35John Coogan?

  Yeah. What is their AI revenue today? Is it just Grok subscriptions plus Grok tokens? Do you include X subscriptions? Do you include cloud vendor and Neo cloud contracts? There's a bunch of different ways to measure it. The smaller the number, the easier it is to 100X. But we have seen other AI companies 100X revenues over two years, over three years, four years. Like the 100X has become, it's not a one of one scenario. It's happened multiple times. And so we have seen these charts many times. And if they execute well, this is entirely possible. It is extremely.

• 18:12Jordi Hays?

  Other notable data points from the roadshow. They, the forecast anticipates SpaceX making about 360 billion of capital expenditures through 2028. Jensen somewhere fist pumping. Very excited about that number. Be a new hyperscaler. Should be unsurprising, but very aggressive.

• 18:33John Coogan?

  Yeah.

• 18:33Jordi Hays?

  And.

• 18:34John Coogan?

  The new Nvidia foundation model is also live. We'll have to go check it out and look at the model card soon. See how it's benchmarking. But we got to move on to benchmark because there's new news in the benchmark world. So.

• 18:48Jordi Hays?

  Moment of silence?

• 18:49John Coogan?

  Moment of silence. Why is that?

• 18:50Jordi Hays?

  For the end of an era.

• 18:53John Coogan?

  I guess, I guess they have been very focused for decades.

• 18:56Jordi Hays?

  The last tier one, there was a pure venture capital.

• 18:59John Coogan?

  What did they get called again? Internet boys or something?

• 19:03Jordi Hays?

  Oh.

• 19:03John Coogan?

  Soft boys. There was some book about them that was very funny.

• 19:07Jordi Hays?

  Yeah. E-boys.

• 19:08John Coogan?

  E-boys. E-boys is a hit piece of a book title.

• 19:12Jordi Hays?

  That was a fantastic book.

• 19:13John Coogan?

  But the subtitle makes up, makes up for it. And it's a fantastic book. And it's a very interesting story where they actually let a journalist come in and see how they.

• 19:21Jordi Hays?

  E-boys, the true story of the six tall men.

• 19:23John Coogan?

  Yeah.

• 19:24Jordi Hays?

  Who backed eBay, Webvan.

• 19:25John Coogan?

  He clearly wrote the subtitle and was like, I gotta take the edge off of this. It's too glazy. I gotta, I gotta take it down a notch. And so he threw the E-boys in there.

• 19:35Jordi Hays?

  But anyways, big moves from Benchmark. Kate Clark has a scoop in the Journal. Benchmark has raised $2 billion across two new funds.

• 19:42John Coogan?

  Wow.

• 19:43Jordi Hays?

  And most notably their first ever dedicated growth fund.

• 19:47John Coogan?

  Did they hire anyone who has experience growth investing? Who could possibly do growth investing there? Someone who's maybe like at Bond Capital and then Founder's Fund, then maybe Kleiner, like someone with that pedigree.

• 19:58Jordi Hays?

  Yeah, somebody with that kind of background, I think would be fantastic.

• 20:00John Coogan?

  Pretty good for growth investing.

• 20:02Jordi Hays?

  Now that you say that, though.

• 20:04John Coogan?

  Yeah.

• 20:05Jordi Hays?

  Ev Randall.

• 20:05John Coogan?

  Ev Randall, that's right.

• 20:07Jordi Hays?

  They did pick up Ev Randall.

• 20:08John Coogan?

  They did pick him up. They're almost thinking two steps ahead there.

• 20:12Jordi Hays?

  Are they building their fund strategy now, their entire platform strategy around Ev Randall?

• 20:16John Coogan?

  Potentially, potentially.

• 20:18Jordi Hays?

  Austin-based podcaster Joe Rogan reportedly being considered for 60 Minutes.

• 20:23John Coogan?

  60 Minutes. They're gonna have to call it 200 Minutes. Cause he records long podcasts in 60 Minutes. Isn't it enough for him?

• 20:30Jordi Hays?

  Hundreds. It'll just be called Hundreds of Minutes.

• 20:32John Coogan?

  Barry, if you're listening, put us in. Put us in the ring. We're ready to go. You need tech correspondent, business correspondent, someone who can just chop it up for 60 Minutes. We do 60 Minutes three times a day. We're ready to go. This is gonna be light work for us, Barry. I'm ready, I'm ready. You could do 60 Minutes right now. You could do 60 Minutes tomorrow. You could do 60 Minutes. You could do an extra 60 Minutes easily. We're putting up a thousand minutes a week. It's no problem.

• 20:56Jordi Hays?

  We did consider that at one point early on. We thought, should we do basically a morning show?

• 21:01John Coogan?

  Oh, yeah.

• 21:02Jordi Hays?

  Take a two-hour break and come back and do another show.

• 21:04John Coogan?

  Late-night show. Yeah, late-night show, maybe. Anyway, we should talk about the new Audi, the Nuvo Lari. Is this real? Motor One? This seems real.

• 21:12Jordi Hays?

  It's real.

• 21:13John Coogan?

  It's a big deal. It's the brand's first supercar since the R8. Twin-turbocharged, 4-liter V8 Hybrid, 217 mile-per-hour top speed. That is 10% faster than a Cayenne Turbo GT. What is the Cayenne Turbo GT market doing right now? Is it tanking? Depreciation must be just through the roof on this news because you have a car that's 10% faster. And so everyone is gonna be rotating out of Turbo GTs, I imagine.

• 21:40Jordi Hays?

  I think the Nuvo Lari looks amazing.

• 21:43John Coogan?

  It's a really cool design.

• 21:44Jordi Hays?

  Feels like somewhat Cybertruck-inspired.

• 21:47John Coogan?

  Cyberpunk-y, futuristic. I don't know. It just checks the box for like the next supercar for me. And in a way that the-

• 21:54Jordi Hays?

  Ben says it can't touch the R8.

• 21:55John Coogan?

  Oh, can't touch the R8? Okay. Okay. Well, it goes 0 to 16 in 2.6 seconds.

• 22:00Jordi Hays?

  Thank you for tuning in with us today, folks. We will be back on Monday.

• 22:05John Coogan?

  Yes.

• 22:06Jordi Hays?

  And we look forward to it.

• 22:07John Coogan?

  Some business to do tomorrow, but see you Monday. Leave us five stars on Apple Podcasts and Spotify. Sign up for the newsletter, tptn.com and have a wonderful weekend. We'll see you later.

• 22:16Jordi Hays?

  We love you.

• 22:16John Coogan?

  Goodbye.